Sponsor: NRG
Sponsor Study ID: NRG-HN011
Study Title: A Randomized Phase II Study of Nivolumab versus Nivolumab and BMS-986016 (Relatimab) as Maintenance Treatment after First-line Treatment with Platinum-Gemcitabine-Nivolumab for Patients with Epstein-Barr Virus- Associated Recurrent/Metastatic Nasopharyngeal Carcinoma (REMAIN)
CTO #: 104051
NCT Number: NCT06029270
Phase: II
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Lip, Oral Cavity and Pharynx
Study Objectives: To determine if adding BMS-986016 to nivolumab maintenance therapy shows a signal of improved progression free survival according to RECIST 1.1 in patients who do not progress following treatment with platinum gemcitabine nivolumab combination in the first line treatment of recurrent and/ or metastatic nasopharyngeal carcinoma.